Our research program conducts translational studies that seek to identify and characterize regulators drug disposition that ultimately promote variability in treatment success or severity of toxicities experienced by cancer patients. We currently focus on the role of transporter proteins in regulating drug or nutrient uptake and accumulation.
Education and Training:
Postdoctoral Fellow, Pharmaceutical Sciences, St. Jude Children‘s Research hospital (2014)
PhD, Biomolecular Sciences, Laurentian University (2010)
BS, Biochemistry, Laurentian University (2004)
Assistant Professor, Pharmaceutical Sciences, University at Buffalo (2018-present)
Assistant Professor, Pharmaceutical, Social and Administrative Sciences, D'Youville College (2014–2018)
Leblanc AF, Sprowl JA, Alberti P, Chiorazzi A, Arnold WD, Gibson AA, Hong KW, Pioso MS, Chen M, Huang KM, Chodisetty V, Costa O, Florea T, de Bruijn P, Mathijssen RH, Reinbolt RE, Lustberg MB, Sucheston-Campbell LE, Cavaletti G, Sparreboom A, Hu S. OATP1B2 deficiency protects against paclitaxel-induced neurotoxicity. J Clin Invest. 2018; 128(2).
Sprowl JA, Ong SS, Gibson AA, Hu S, Du G, Lin W, Li L, Bharill S, Ness RA, Stecula A, Offer SM, Diasio RB, Nies AT, Schwab M, Cavaletti G, Schlatter E, Ciarimboli G, Schellens JH, Isacoff EY, Sali A, Chen T, Baker SD, Sparreboom A, Pabla N. A phosphotyrosine switch regulates organic cation transporters. Nat Commun. 2016; 7.